Cor Vasa 2011, 53(1-2):60-67

Specific features of care for patients after heart transplantation

Lenka Hošková1,*, Mariana Podzimková1, Ivan Málek1, Markéta Hegarová1, Zora Dorazilová1, Ivan Netuka2, Josef Kautzner1, Jan Pirk2
1 Klinika kardiologie
2 Klinika kardiovaskulární chirurgie, Institut klinické a experimentální medicíny, Praha, Česká republika

Heart transplantation is now an established modality of treatment reserved for patients with end-stage heart failure when other therapeutic options have failed. The clinical heart transplant program was launched at the Institute for Clinical and Experimental Medicine in 1984. Since then, 785 heart transplant procedures have been performed by the end of August 2010. Based on our own experience, improving outcomes depend not only on improved surgical techniques but also on advances in immunosuppressive therapy. Clinical follow-up of heart transplant recipients brings some specific problems, mainly graft rejection, opportunistic infections, malignancies, graft coronary disease, and adverse effects of immunosuppressive prophylaxis. Therefore, a specialized outpatient clinic and cooperation of different medical subspecialities are important in the management of these patients.

Keywords: Heart transplantation; Immunosuppressive agents; Rejection; Infection; Malignancies

Published: January 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hošková L, Podzimková M, Málek I, Hegarová M, Dorazilová Z, Netuka I, et al.. Specific features of care for patients after heart transplantation. Cor Vasa. 2011;53(1-2):60-67.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Taylor DO, Stehlík J, Edwards LB, et al. Registry of International Society for Heart and Lung Transplantation: Twenty-sixth official adult heart transplant report - 2009. J Heart Lung Transplant 2009;28:1007-1023. Go to original source... Go to PubMed...
    2. Málek I. Transplantace srdce. Pohled kardiologa. Praha: Triton, 2004.
    3. Kočandrle V, Fabián J, Firt P. Transplantace srdce. Čas Lék Čes 1984;123: 1297-1302.
    4. Stewart S, Winter GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Transplant 2005;24:1710-1720. Go to original source... Go to PubMed...
    5. Podzimková M, Gebauerová M, Málek I, et al. Infekční komplikace nemocných po transplantaci srdce. Cor Vasa 1993;35:263-266.
    6. Kocík M, Málek I, Glagoličová A, et al. The effect of cyclosporin A on the level of big endotelin in patients one year after orthotopic heart transplantation. Transplant Int 2004;17:65-70. Go to original source... Go to PubMed...
    7. Welnhofer E, Hermann NE, Hug J, et al. A decade of percutaneous coronary interventions in cardiac transplant recipients: A multicentric study in 16 patients. J Heart Transplant 2008;27:17-25. Go to original source... Go to PubMed...
    8. Smith JA, Ribakova GH, Hunt SA, et al. Heart retransplantation: the 25 year experience at a single institution. J Heart Lung Transplant 1995;14:832-839.
    9. Raichlin E, Bae JH, Khalpey Z, et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 2007;116:2726-2733. Go to original source... Go to PubMed...
    10. Valantine H, Zuckermann A. From clinical trials to clinical practice: An overview of everolimus in heart transplantation. J Heart Lung Transplant 2005;24:S185-S190. Go to original source... Go to PubMed...
    11. Valantine H. Cardiac allograft vasculopathy after heart transplantation: Risk factors and management. J Heart Lung Transplant 2004;23:187-193. Go to original source... Go to PubMed...
    12. Viklický O, Podzimková M, Matl I, et al. Renal function in cyclosporine-treated heart transplant recipients: long-term follow-up. Cor Vasa 1999;41:131-134.
    13. Garrido IP, Crespo-Leiro MG, Paniagua MJ, et al. Independent predictors of renal dysfunction after heart transplantation in patients with normal pretransplant renal function. J Heart Lung Transplant 2005;24:1226-1230. Go to original source... Go to PubMed...
    14. Hošková L, Viklický O, Málek I, et al. Ischaemic heart disease is a risk factor for renal failure after heart transplantation. Int J Cardiol 2008;123:358-360. Go to original source... Go to PubMed...
    15. Hunt J, Lerman M, Magee MJ, et al. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation. J Heart Transplant 2005;24:1863-1867. Go to original source... Go to PubMed...
    16. Jandová R, Fabián J. Výskyt systémové hypertenze po ortotopické transplantaci srdce. Čas Lék Čes1990;129:16-19.
    17. Kobashigawa JA, Katznelzon S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-627. Go to original source... Go to PubMed...
    18. Špinarová L, Toman J, et al. Fluvastatin u pacientů po transplantaci srdce. Vnitř Lék 1998;44:13-16. Go to PubMed...
    19. Hošková l, Málek I, Podzimková M. Bezpečnost a účinnost fluvastatinu po transplantaci srdce. Cor Vasa 2004;46:473-477.
    20. Lemahieu WP, Hermann M, Asberg A, et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transpl 2005;5:2236-2243. Go to original source... Go to PubMed...
    21. Skalická B, Kubánek M, Málek I, et al. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin. J Heart Lung Transplant 2009;28:598-604. Go to original source... Go to PubMed...
    22. Hošková L, Málek I, Podzimková M, et al. Výskyt nádorových onemocnění u pacientů po transplantaci srdce. Onkologie 2008;2:123-127.
    23. Valantine H. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology. J Heart Lung Transplant 2007;26:557-564. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes